In our study, the sensitivity and specificity of the novel evaluation for CRC diagnosis were 97.96% and 88.71%, respectively, which were higher than the sensitivity and specificity of KRAS mutation and BMP3 and NDRG4 methylation status, separately (46.94% and 88.39%, 83.67% and 84.19%). Here, KRAS is linked to colorectal carcinoma.